News and Events
Stay informed about RECOVER’s Long COVID research by reading the latest news and participating in upcoming events.

Stay informed about RECOVER’s Long COVID research by reading the latest news and participating in upcoming events.

Biostatisticians and clinicians work together to help funded study teams access resources stored in RECOVER’s biorepository, a unique collection of biosamples from almost 30,000 adults and children.
RECOVER pathobiologists have designed a large, collaborative, and innovative study that can help to develop diagnostics for specific types of Long COVID.
NIH leaders and RECOVER researchers will provide updates on RECOVER-Treating Long COVID (RECOVER-TLC), the next phase of RECOVER Long COVID clinical trials.
RECOVER released a call for ancillary pathobiology study proposals that will build on the more than 60 existing funded studies and will address unanswered questions about Long COVID.
This year, RECOVER researchers continue to publish results from research studies that deepen our understanding of Long COVID. RECOVER studies continue, with 2 clinical trials expected to reach enrollment goals this summer.
RECOVER is funding 60+ pathobiology studies to explore how cells in the body interact with each other to cause Long COVID symptoms. These findings may lead to better ways to diagnose, treat, and prevent Long COVID.
Five RECOVER study sites across the Pacific Northwest teamed up to form a consortium. Consortium members learn from other RECOVER researchers’ findings and share knowledge with the community.
During the December 10th RECOVER Research Review (R3) Seminar, researchers described a recent pathobiology study investigating viral persistence, or when SARS-CoV-2 remains in a person’s body and continues to cause changes even after they recover from their initial sickness. The study’s findings suggest that viral persistence could be one reason why some people experience certain symptoms of Long COVID.